Rocci Mario L, Devanarayan Viswanath, Haughey David B, Jardieu Paula
Department of Bioanalytical Sciences, Prevalere Life Sciences Inc., Whitesboro, NY 13492, USA.
AAPS J. 2007 Oct 5;9(3):E336-43. doi: 10.1208/aapsj0903040.
Bioanalytical methods used to support the drug development process are validated to ensure that they function in the manner in which they are intended. "Incurred" or study samples can vary in their composition when compared with the standards and quality control samples used to validate the method and analyze these samples. During the 3rd American Association of Pharmaceutical Scientists(AAPS)/Food and Drug Administration(FDA) Bioanalytical Workshop, it was suggested that the reproducibility in the analysis of incurred samples be evaluated in addition to the usual prestudy validation activities performed. This manuscript provides recommendations concerning the number and types of samples that should be analyzed in such an evaluation, as well as the manner in which the resultant data should be analyzed. Suggestions as to follow-up activities and data reporting are also discussed. This approach is at best a beginning and is offered as a platform for future discussion, comments, and revision.
用于支持药物研发过程的生物分析方法需经过验证,以确保其按预期方式运行。与用于方法验证和分析这些样本的标准品及质量控制样本相比,“实际检测的”或研究样本的成分可能会有所不同。在美国药物科学家协会(AAPS)/食品药品监督管理局(FDA)第三届生物分析研讨会上,有人建议除了进行常规的研究前验证活动外,还应评估实际检测样本分析的重现性。本手稿就此类评估中应分析的样本数量和类型,以及所得数据的分析方式提供了建议。还讨论了后续活动和数据报告的相关建议。这种方法充其量只是一个开端,旨在为未来的讨论、评论和修订提供一个平台。